Schizophrenia, psychosis, and cerebral spinal fluid homovanillic acid concentrations

J. W. Maas, C. L. Bowden, A. L. Miller, M. A. Javors, L. G. Funderburg, N. Berman, S. T. Weintraub

Research output: Contribution to journalArticle

18 Scopus citations

Abstract

Neuroleptic drugs block brain dopamine receptors and are effective in treating psychoses of diverse origins. This Finding has become a cornerstone of the dopamine theory of schizophrenia, but clinical studies relating schizophrenia, per se, to brain dopamine metabolism have ranged from controversial to negative. This article presents new evidence that cerebrospinal fluid levels of the dopamine metabolite homovanillic acid are related to the severity of psychosis in schizophrenia. These results support the concept that homovanillic acid levels in cerebrospinal fluid vary as a function of psychosis rather than being related to the diagnosis of schizophrenia per se.

Original languageEnglish (US)
Pages (from-to)147-154
Number of pages8
JournalSchizophrenia bulletin
Volume23
Issue number1
DOIs
StatePublished - Dec 1 1997

ASJC Scopus subject areas

  • Psychiatry and Mental health

Fingerprint Dive into the research topics of 'Schizophrenia, psychosis, and cerebral spinal fluid homovanillic acid concentrations'. Together they form a unique fingerprint.

  • Cite this

    Maas, J. W., Bowden, C. L., Miller, A. L., Javors, M. A., Funderburg, L. G., Berman, N., & Weintraub, S. T. (1997). Schizophrenia, psychosis, and cerebral spinal fluid homovanillic acid concentrations. Schizophrenia bulletin, 23(1), 147-154. https://doi.org/10.1093/schbul/23.1.147